Company Performance Drug Development Drug Sales Market Performance Drug Approval Market Analysis Eli Lilly Drug Approvals Earnings Reports Pfizer Torrent Pharmaceuticals Moderna Vaccines Vaccine Development Sales Performance Lupin AstraZeneca Market Trends Indian Pharma Sector Merck Medications Bristol Myers Squibb Production Expansion Drug Launches Revenue Drug Companies Corporate Earnings Mergers and Acquisitions Weight Loss Exports Manufacturing Opioid Crisis Regulatory Compliance Company Acquisitions Market Dynamics Biotechnology Market Reactions Merck & Co. Public Companies Peer Comparison Tariffs Online Pharmacies Partnerships Chinese Drug Makers Drug Pricing Drug Acquisition Sanofi Generic Medicines Sales Analysis Global Sales Product Management Profitability Generic Drugs Regulatory Affairs Market Competition Innovative Drugs Strategic Planning Competitors Revenue Growth Sales Trends Drug Manufacturing Dermatology Sai Life Sciences Oncology Drug Funding Health Sales Growth COVID-19 Vaccines Vaccine Sales Weight-loss Drugs Weight-Loss Drugs Corporate Performance COVID-19 Treatments Licensing Agreements Axsome Therapeutics Earnings Pharmaceutical Companies Healthcare Product Performance Product Launches Regulatory Approvals R&D Expenses
An FDA decision on a subcutaneous starting dose for Leqembi is due by May 24.
